...A. Currently, we are on track for a supplemental NDA for pegcetacoplan in early 2025, with an EU filing by Sobi also expected for next year. B. They're randomized 1:1, either to pegcetacoplan, 1,080 milligrams, subcutaneous infusion twice weekly or to placebo. C. The only thing I really want to highlight here for you is that it does look like the placebo group with an 87 milliliter per minute GFR had slightly better kidney function coming into this study. D. The primary endpoint is log transformed ratio of your protein-to-creatinine ratio at that 26 weeks, but a number of other key secondary endpoints, which include achieving a composite renal endpoint and that includes greater than or equal to a 50% reduction in urine protein and stabilization of the glomerular filtration. E. So a less than or equal to 15% change reduction in that GFR. F. We also studied the reduction of the number of patients or proportion of patients that actually reduce their urine protein by at least 50%. G. Highly,...
